High Rates of Pathological Complete Response in Patients with Advanced Esophageal Cancer in OPAXIO™ Phase II Study Reported in American Journal of Clinica... ( SEATTLE Feb. 23 2011 /- Cell Therapeu...)

HOME >> MEDICINE >> TECHNOLOGY

High Rates of Pathological Complete Response in Patients with Advanced Esophageal Cancer in OPAXIO™ Phase II Study Reported in American Journal of Clinical Oncology

Date:2/23/2011

SEATTLE, Feb. 23, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that updated phase II study results of OPAXIO (paclitaxel poliglumex) in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% (15/40) of the patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response. A pathological complete response, observed in 32% of patients in the study, is recorded only when the esophagus is surgically removed after therapy and no tumor can be found microscopically. In historical studies, pathologic complete response has correlated with prolonged survival.

"We are pleased to have the impressive and potentially important results of the paclitaxel poliglumex phase II esophageal study published in a peer reviewed journal," said Dr. Howard Safran, M.D., director of the Brown University Oncology Group. "In this study, the treatment was well tolerated and we did not see the severe side effects that are typically experienced with standard treatment options. If these data can be validated in a randomized controlled trial, the use of paclitaxel poliglumex along with cisplatin and radiation could provide an important treatment alternative for patients with lower esophageal cancer with an attractive risk-benefit profile."

The phase II study conducted by the Brown University Oncology Group enrolled 40 patients with pathologically-confirmed, locally-advanced adenocarcinoma or squamous cell carcinoma of the esophagus or gastro-esophageal junction with no evidence of distant metastases. The patients received weekly paclitaxel poliglumex (50mg/m2) and cisplatin (25mg/m2) for six weeks with concurrent 50.5Gy of radiation. The updated data demonstrated
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
4. GlaxoSmithKline Accelerates Review of Exelixis XL880
5. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
6. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
7. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
8. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
9. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
10. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
11. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial

Post Your Comments:

(Date:5/23/2013)... 2013 More than half of women diagnosed ... chemotherapy and still have excellent outcomes. To educate women, ... the largest sources of online consumer information about breast ... page provide recently diagnosed women with information sources, to ... "We anticipate these innovative social media campaigns ...

(Date:5/23/2013)... , May 23, 2013 Hologic, Inc. ... ), a leading developer, manufacturer and supplier of ... with an emphasis on serving the healthcare needs ... observational study in a U.S. clinical practice comparing ... (breast tomosynthesis) with conventional 2D mammography alone showed ...

(Date:5/23/2013)... BioElectronics Corporation (OTC Pink: BIEL), the maker of ... FDA panel meeting for non-thermal shortwave diathermy: ... Therapy Meeting was held on May 21, 2013 in ... of the meeting was very narrow, in that the ... the application of non-thermal shortwave diathermy for the treatment ...

Breaking Medicine Technology:Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2 Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3 First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 2 First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 3 First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 4 BioElectronics and Pulsed Shortwave Therapy Make Progress 2

[0] Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions [0] First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection [0] BioElectronics and Pulsed Shortwave Therapy Make Progress

... , , , PORTLAND, ... administration of the H1N1 vaccine and to encourage members to ... costs associated with the administration of the H1N1 vaccine during ... members covered by its insured plans. Regence will strongly encourage ...

... , , , ... today from the COMPARE trial demonstrated that Abbott,s (NYSE: ... System demonstrated significantly better outcomes in key safety and efficacy ... (TAXUS). At one year, XIENCE V demonstrated a significantly lower ...

Cached Medicine Technology:Regence to Cover Administration Costs of H1N1 Vaccine for Fully-Insured Groups, Individuals This Flu Season 2 Regence to Cover Administration Costs of H1N1 Vaccine for Fully-Insured Groups, Individuals This Flu Season 3 Abbott's XIENCE V(R) Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COMPARE Trial 2 Abbott's XIENCE V(R) Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COMPARE Trial 3

Regence to Cover Administration Costs of H1N1 Vaccine for Fully-Insured Groups, Individuals This Flu Season Abbott's XIENCE V(R) Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COMPARE Trial

(Date:5/24/2013)... commonly used to treat glaucoma may cause droopy eyelids ... according to a new study. The drugs, known ... eye pressure, have already been shown to cause blurred ... said, suggesting that the new findings could lead to ... conservative when prescribing these drugs, the researchers added, particularly ...

(Date:5/24/2013)... New York (PRWEB) May 24, 2013 Let’s ... teeth. It is not uncommon for the majority of people ... Whether it is due to a coffee addiction or simply ... why whitening procedures are so popular. , Herald ... new and very effective whitening system: Venus White Max. ...

(Date:5/24/2013)... 2013 Area homeowners dreaming about owning a ... tubs to choose from at factory-direct pricing during the ... event takes place at Emerald Pool and Patio ... Jacuzzi, the industry's leading hot tub brand, scheduled the event ... The event will feature popular hot tub models at up ...

(Date:5/24/2013)... May 24, 2013 The nation’s first ... Intuitive Surgical Inc.’s da Vinci Surgical System concluded yesterday, ... a Washington State Court jury ruled in a 10-to-2 ... a surgeon who performed a da Vinci prostatectomy on ... patient’s family had alleged in their lawsuit that the ...

(Date:5/24/2013)... infantile myofibromatosis (IM)a disorder characterized by multiple tumors involving ... targets, according to researchers from the Icahn School of ... American Journal of Human Genetics , may lead ... which the only current treatment option is repeated surgical ... disorder that develops in infancy or even in utero ...

Breaking Medicine News(10 mins):Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2 Health News:Herald Square Dental Introduces New In-office Whitening System: Venus White Max 2 Health News:Truckload of Jacuzzi® Hot Tubs Rolls into Bend, Oregon on May 24, 2013 for Sales Event 2 Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 2 Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 3 Health News:Researchers identify first drug targets in childhood genetic tumor disorder 2

[0] Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds [0] Herald Square Dental Introduces New In-office Whitening System: Venus White Max [0] Truckload of Jacuzzi® Hot Tubs Rolls into Bend, Oregon on May 24, 2013 for Sales Event [0] Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications [0] Researchers identify first drug targets in childhood genetic tumor disorder

... transplantation reliably yield grafts for two adults? Experts consider ... the July issue of Liver Transplantation , a ... also available online at Wiley Interscience ( www.interscience.wiley.com ). ... advanced surgical strategies to increase opportunities for those in ...

... , ... ROUND ROCK, Texas (Business Wire EON) June 30, ... the mantra that ,more is better, when it comes to managing ... Life Sciences. "Virtualizing the IT infrastructure fully illustrates the idea that ...

... PLANTATION, Fla., June 30 To further growth ... service and,medical management operations, Broadspire has made several ... -- Dennis Replogle, currently chief executive officer, becomes ... currently president of Broadspire, also will,assume the responsibilities ...

... PRUSSIA, Pa., June 30 TMG Health announced,today that ... of the,Ernst & Young Entrepreneur Of The Year(R) 2008 ... the awards program was designed to,recognize outstanding entrepreneurs on ... leading dynamic, growing businesses. Jack Tighe,was selected as a ...

... Declaration Survey, SEOUL, Korea, June 30 ... the workplace and keeping,it top of mind with ... keeping employees safe, according to a DuPont-sponsored survey ... The survey results are the basis for the ...

... FORT WORTH, Texas, June 30 Wound Management,Technologies, ... signing,of a commission based, sales agreement for its ... (EWA GSI). This agreement,follows discussions and demonstrations, and ... role in international wound management.,CellerateRx patented collagen fragments ...

Cached Medicine News:Health News:Experts examine challenges of split liver transplantation 2 Health News: Virtualization with Dell Helps Cure Growing Health Care IT Ills 2 Health News: Virtualization with Dell Helps Cure Growing Health Care IT Ills 3 Health News: Virtualization with Dell Helps Cure Growing Health Care IT Ills 4 Health News:Broadspire Announces Key Leadership Appointments 2 Health News:Broadspire Announces Key Leadership Appointments 3 Health News:TMG Health President and CEO Jack Tighe Named Ernst & Young Entrepreneur Of The Year(R) 2008 in Philadelphia Region 2 Health News:TMG Health President and CEO Jack Tighe Named Ernst & Young Entrepreneur Of The Year(R) 2008 in Philadelphia Region 3 Health News:Companies Report Success in Driving Safety Culture at Workplaces 2 Health News:Companies Report Success in Driving Safety Culture at Workplaces 3 Health News:Companies Report Success in Driving Safety Culture at Workplaces 4 Health News:Wound Management Technologies, Inc. Announces Sales Agreement with EWA Government Systems, Inc. 2 Health News:Wound Management Technologies, Inc. Announces Sales Agreement with EWA Government Systems, Inc. 3

Experts examine challenges of split liver transplantation Virtualization with Dell Helps Cure Growing Health Care IT Ills Broadspire Announces Key Leadership Appointments TMG Health President and CEO Jack Tighe Named Ernst & Young Entrepreneur Of The Year(R) 2008 in Philadelphia Region Companies Report Success in Driving Safety Culture at Workplaces Wound Management Technologies, Inc. Announces Sales Agreement with EWA Government Systems, Inc.

Knot pusher/suture retriever...

Single step suture passage is made simple with Arthro-Pierce instruments. The low profile, highly sharpened tip allows easy passage through tissue in order to retrieve or apply suture....

Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand ...

Medicine Products:

CrabClaw Knot Pusher/Suture Retriever Arthro-Pierce Instrument System BirdBeak Suture Passer, Left, 45 Handle Viper Suture Passer